Partner With Us NRI

Sun Pharmaceuticals Industries Ltd share Price Today

Company details

6M Return 21.80%
1Y Return 21.42%
Mkt Cap.(Cr) 296,509.82
Volume 1,612,113
Div Yield 0.93%
OI Chg %
Volume 1,612,113

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Numbers in line despite Taro weakness, below-par India
About The Stock

    Sun is the world’s fourth largest specialty generic company with sales of US$3.8 billion and boasts of 43 manufacturing sites addressing segments like specialty products, branded generics, complex generics, pure generics and APIs.

    • With a market share of 8.2%, Sun is ranked No. 1 in domestic formulations. It enjoys leadership position in 11 specialties based on prescription
    • Revenue breakup: US formulation~30%, Indian branded~30%, Emerging markets~17%, RoW~14%, API & Others~6%

    Strong set of numbers in line with our estimates amid strong momentum across business verticals.

    • Sales were up 11.6% YoY to ₹ 9863.1 crore
    • EBITDA was at ₹ 2606.3 crore, up 8.3% YoY with margins at 26.4%
    • Adjusted PAT was at ₹ 2058.8 crore (up 11.1% YoY)

Click here for full recommendation

Research view on more stocks

Sun Pharmaceutical Industries announced Q2FY24 & H1FY24 results:

  • Consolidated Q2FY24:
    • Gross sales at Rs 1,20,031 million, growth of 11.0% vs Q2FY23
    • India formulation sales at Rs 38,425 million, up 11.1% vs Q2FY23
    • US formulation sales at USD 430 million, up 4.2% vs Q2FY23
    • Global specialty sales at USD 240 million, up 19.3% vs Q2FY23
    • Global specialty sales accounted for 16.4% of Q2FY24 sales
    • Emerging Markets formulation sales at USD 284 million, up 9.4% vs Q2FY23.
    • Rest of World formulation sales at USD 206 million, up 13.7% vs Q2FY23
    • R&D investments at Rs 7,734 million (6.4% of sales) compared to Rs 5,710 million (5.3% of sales) for Q2
      last year
    • EBITDA at Rs 31,794 million (including other operating revenues), up 7.5% vs Q2FY23. EBITDA
      margin for Q2FY24 at 26.1% vs 27% for Q2FY23.
    • Net profit for the quarter was at Rs 23,755 million, up 5% YoY
  • Consolidated H1FY24:
    • Gross sales at Rs 2,37,883 million, a growth of 10.9% over H1FY23
    • India formulation sales at Rs 74,029 million, up 8.1% over H1FY23
    • US formulation sales at USD 901 million up by 8.2% over H1FY23
    • Emerging Markets formulation sales at USD 545 million up by 8.0% over H1FY23
    • Rest of World formulation sales at USD 401 million up by 8.0% over H1FY23
    • EBITDA at Rs 65,112 million (including other operating revenues), up 11.5% over H1FY23, with a resulting EBITDA margin of 27%
    • Net profit for H1FY24 was at Rs 43,981 million. Excluding the exceptional items of H1 current year, adjusted net profit was up by 9.2%

Dilip Shanghvi, Managing Director of the Company said, “US FDA’s acceptance of deuruxolitinib NDA for treatment of moderate to severe alopecia areata marks an important milestone. There are limited treatment options for alopecia areata and deuruxolitinib should make a meaningful difference in patient lives, once approved. Similarly, another late stage candidate Nidlegy will potentially complement our Odomzo franchise. Nidlegy’s recent positive phase-3 data in patients with locally advanced fully resectable melanoma positions us to provide patient solutions across a broad spectrum of skin cancers.”


Result PDF

View Other Company Results


Investment recommendation
Numbers in line despite Taro weakness, below-par India
Call Date
01 Feb 2023
Entry Price 1,040.00
Target Price 1,210.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Sun Pharmaceuticals Industries Ltd Stocks COMPARISION


Equity Capital: 55,995.38 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 20,486.67 41,311.63
LAST 3M 59,182.99 18,817.17
LAST 6M 99,630.35 93,158.70
LAST 12M 166,983.77 138,194.89
Sun Pharmaceutical Industries Limited - Change in Management

Dec 08, 2023 l NSE Announcement

Sun Pharma enters into licensing agreement with Aclaris Therapeutics Inc.

Dec 06, 2023 l BSE Announcement

Sun Pharmaceutical Industries Limited - Loss of Share Certificates

Dec 04, 2023 l NSE Announcement

Date Action Type Ratio
Jul 28, 2023 Dividend 400
Feb 08, 2023 Dividend 750
Aug 19, 2022 Dividend 300

Sun Pharmaceuticals Industries Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Sun Pharmaceuticals Industries Ltd. is the fourth-largest speciality generic pharmaceutical company in the world. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries worldwide. The company was founded in 1983 with its headquarters in Mumbai. For the quarter ended June 2022, Sun Pharmaceuticals Industries Ltd.’s total income was Rs HYPERLINK "https://economictimes.indiatimes.com/sun-pharmaceutical-industries-ltd/stocks/companyid-9134.cms" 10,763.90 crore, up 12.59% from the previous financial year. On 5 August 2022, the company’s market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/sunpharmaceuticalindustries/SPI" 219,767 crore.  

    Sun Pharmaceuticals Industries Ltd. is listed on the Bombay Stock Exchange with the code 524715. It is listed on the National Stock Exchange with the code SUNPHARMA. It is also listed on the MCX Stock Exchange. 

    Sun Pharmaceuticals Industries Ltd. has more than 40 manufacturing facilities. Its product portfolio consists of generics, branded generics, over-the-counter (OTC), difficult-to-make technology-intensive products, antiretrovirals (ARVs), speciality, Active Pharmaceutical Ingredients, and its intermediates. A few flagship OTC brands of the company include Revital, Volini, and Faringosept. 

    As of 30 June 2022, the company’s shareholding pattern indicated a promoter stake of 54.48%, foreign institutional investor stake of 14.95%, domestic institutional investor stake of 19.67%, and public stake of 10.91%. During the quarter ended June 2022, promoters unpledged 1.53% of shares, making the total promoter pledge stand at 4.04%. The mutual fund holdings increased from 11.63% to 11.84%, while the promoter’s holding remained unchanged. The total shares outstanding were 239.93 crores.  

    The company’s chairman is Mr Israel Makov. The founder and managing director isMr Dilip Sanghvi. The North American CEO is Mr Abhay Gandhi. Ms Kirti Ganorkar is the India CEO. The other members of the top management comprise Mr Anilkumar Jain, Mr Kalyanasundaram Subramanian, Mr Sudhir V Valia, Dr Pawan Goenka, Mr Rama Bijapurkar, and Mr Gautam Doshi, among others. The auditors are SRBC & Co. LLP.  

    On 5 August 2022, the share price of Sun Pharmaceuticals Industries Ltd. closed at Rs 916.35 on BSE and at Rs 915.95 on NSE. The 52-week high for Sun Pharmaceuticals Industries Ltd.’s share price was Rs 967.05, and the 52-week low for the company’s share price was Rs 733.70. 

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Sun Pharma Advanced Res.Centre, Tandalja, Vadodara, Gujarat, 390020

Tel : 91-265-6615500
Email : secretarial:sunpharma.com
Website : http://www.sunpharma.com

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524715
Book Closure Date (Month) :
BSE Group : A
ISIN : INE044A01036

FAQ’s on Sun Pharmaceuticals Industries Ltd Shares

You can buy Sun Pharmaceuticals Industries Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Sun Pharmaceuticals Industries Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Dec 08, 2023 03:57 PM the closing price of Sun Pharmaceuticals Industries Ltd was ₹ 1,235.80.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 08, 2023 03:57 PM, the market cap of Sun Pharmaceuticals Industries Ltd stood at ₹ 296,509.82.

The latest PE ratio of Sun Pharmaceuticals Industries Ltd as of Dec 08, 2023 03:57 PM is 33.07

The latest PB ratio of Sun Pharmaceuticals Industries Ltd as of Dec 08, 2023 03:57 PM is 0.20

The 52-week high of Sun Pharmaceuticals Industries Ltd is ₹ 1,258.00 while the 52-week low is ₹ 922.45

According to analyst recommendations, Sun Pharmaceuticals Industries Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app